Literature DB >> 32572562

Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases.

Elizabeth C Mormino1, Tyler N Toueg2, Carmen Azevedo3, Jessica B Castillo3, Wanjia Guo4, Ayesha Nadiadwala2, Nicole K Corso2, Jacob N Hall2, Audrey Fan3, Alexandra N Trelle4, Marc B Harrison4, Madison P Hunt4, Sharon J Sha2, Gayle Deutsch2, Michelle James2,3, Carolyn A Fredericks2, Mary Ellen Koran3, Michael Zeineh3, Kathleen Poston2, Michael D Greicius2, Mehdi Khalighi3, Guido A Davidzon3, Bin Shen3, Greg Zaharchuk3, Anthony D Wagner4, Frederick T Chin3.   

Abstract

PURPOSE: In vivo measurement of the spatial distribution of neurofibrillary tangle pathology is critical for early diagnosis and disease monitoring of Alzheimer's disease (AD).
METHODS: Forty-nine participants were scanned with 18F-PI-2620 PET to examine the distribution of this novel PET ligand throughout the course of AD: 36 older healthy controls (HC) (age range 61 to 86), 11 beta-amyloid+ (Aβ+) participants with cognitive impairment (CI; clinical diagnosis of either mild cognitive impairment or AD dementia, age range 57 to 86), and 2 participants with semantic variant primary progressive aphasia (svPPA, age 66 and 78). Group differences in brain regions relevant in AD (medial temporal lobe, posterior cingulate cortex, and lateral parietal cortex) were examined using standardized uptake value ratios (SUVRs) normalized to the inferior gray matter of the cerebellum.
RESULTS: SUVRs in target regions were relatively stable 60 to 90 min post-injection, with the exception of very high binders who continued to show increases over time. Robust elevations in 18F-PI-2620 were observed between HC and Aβ+ CI across all AD regions. Within the HC group, older age was associated with subtle elevations in target regions. Mildly elevated focal uptake was observed in the anterior temporal pole in one svPPA patient.
CONCLUSION: Preliminary results suggest strong differences in the medial temporal lobe and cortical regions known to be impacted in AD using 18F-PI-2620 in patients along the AD trajectory. This work confirms that 18F-PI-2620 holds promise as a tool to visualize tau aggregations in AD.

Entities:  

Keywords:  Alzheimer’s disease; Human aging; Neurofibrillary tangles; Tau PET

Mesh:

Substances:

Year:  2020        PMID: 32572562      PMCID: PMC7755737          DOI: 10.1007/s00259-020-04923-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


  34 in total

1.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

Authors:  Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2011-11-20       Impact factor: 17.088

2.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

Authors:  David T Chien; Shadfar Bahri; A Katrin Szardenings; Joseph C Walsh; Fanrong Mu; Min-Ying Su; William R Shankle; Arkadij Elizarov; Hartmuth C Kolb
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

3.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

Authors:  Rik Ossenkoppele; Daniel R Schonhaut; Michael Schöll; Samuel N Lockhart; Nagehan Ayakta; Suzanne L Baker; James P O'Neil; Mustafa Janabi; Andreas Lazaris; Averill Cantwell; Jacob Vogel; Miguel Santos; Zachary A Miller; Brianne M Bettcher; Keith A Vossel; Joel H Kramer; Maria L Gorno-Tempini; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Brain       Date:  2016-03-08       Impact factor: 13.501

4.  The impact of amyloid-beta and tau on prospective cognitive decline in older individuals.

Authors:  Reisa A Sperling; Elizabeth C Mormino; Aaron P Schultz; Rebecca A Betensky; Kathryn V Papp; Rebecca E Amariglio; Bernard J Hanseeuw; Rachel Buckley; Jasmeer Chhatwal; Trey Hedden; Gad A Marshall; Yakeel T Quiroz; Nancy J Donovan; Jonathan Jackson; Jennifer R Gatchel; Jennifer S Rabin; Heidi Jacobs; Hyun-Sik Yang; Michael Properzi; Dylan R Kirn; Dorene M Rentz; Keith A Johnson
Journal:  Ann Neurol       Date:  2019-01-21       Impact factor: 10.422

5.  Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.

Authors:  Clifford R Jack; Heather J Wiste; Terry M Therneau; Stephen D Weigand; David S Knopman; Michelle M Mielke; Val J Lowe; Prashanthi Vemuri; Mary M Machulda; Christopher G Schwarz; Jeffrey L Gunter; Matthew L Senjem; Jonathan Graff-Radford; David T Jones; Rosebud O Roberts; Walter A Rocca; Ronald C Petersen
Journal:  JAMA       Date:  2019-06-18       Impact factor: 56.272

Review 6.  Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship.

Authors:  Peter T Nelson; Heiko Braak; William R Markesbery
Journal:  J Neuropathol Exp Neurol       Date:  2009-01       Impact factor: 3.685

7.  PET Imaging of Tau Deposition in the Aging Human Brain.

Authors:  Michael Schöll; Samuel N Lockhart; Daniel R Schonhaut; James P O'Neil; Mustafa Janabi; Rik Ossenkoppele; Suzanne L Baker; Jacob W Vogel; Jamie Faria; Henry D Schwimmer; Gil D Rabinovici; William J Jagust
Journal:  Neuron       Date:  2016-03-02       Impact factor: 17.173

8.  Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function.

Authors:  David A Bennett; Julie A Schneider; Robert S Wilson; Julia L Bienias; Steven E Arnold
Journal:  Arch Neurol       Date:  2004-03

9.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

10.  Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Authors:  Michael J Pontecorvo; Michael D Devous; Michael Navitsky; Ming Lu; Stephen Salloway; Frederick W Schaerf; Danna Jennings; Anupa K Arora; Anne McGeehan; Nathaniel C Lim; Hui Xiong; Abhinay D Joshi; Andrew Siderowf; Mark A Mintun
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

View more
  9 in total

Review 1.  Multimodality Imaging in Primary Progressive Aphasia.

Authors:  M Roytman; G C Chiang; M L Gordon; A M Franceschi
Journal:  AJNR Am J Neuroradiol       Date:  2022-08-25       Impact factor: 4.966

Review 2.  Overview of tau PET molecular imaging.

Authors:  Gabriel Cassinelli Petersen; Michelle Roytman; Gloria C Chiang; Yi Li; Marc L Gordon; Ana M Franceschi
Journal:  Curr Opin Neurol       Date:  2022-04-01       Impact factor: 6.283

3.  18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.

Authors:  David N Soleimani-Meigooni; Leonardo Iaccarino; Renaud La Joie; Suzanne Baker; Viktoriya Bourakova; Adam L Boxer; Lauren Edwards; Rana Eser; Maria-Luisa Gorno-Tempini; William J Jagust; Mustafa Janabi; Joel H Kramer; Orit H Lesman-Segev; Taylor Mellinger; Bruce L Miller; Julie Pham; Howard J Rosen; Salvatore Spina; William W Seeley; Amelia Strom; Lea T Grinberg; Gil D Rabinovici
Journal:  Brain       Date:  2020-12-05       Impact factor: 13.501

4.  Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease.

Authors:  Alexandra N Trelle; Valerie A Carr; Edward N Wilson; Michelle S Swarovski; Madison P Hunt; Tyler N Toueg; Tammy T Tran; Divya Channappa; Nicole K Corso; Monica K Thieu; Manasi Jayakumar; Ayesha Nadiadwala; Wanjia Guo; Natalie J Tanner; Jeffrey D Bernstein; Celia P Litovsky; Scott A Guerin; Anna M Khazenzon; Marc B Harrison; Brian K Rutt; Gayle K Deutsch; Frederick T Chin; Guido A Davidzon; Jacob N Hall; Sharon J Sha; Carolyn A Fredericks; Katrin I Andreasson; Geoffrey A Kerchner; Anthony D Wagner; Elizabeth C Mormino
Journal:  Neurology       Date:  2021-01-06       Impact factor: 9.910

Review 5.  Alzheimer's disease - the journey of a healthy brain into organ failure.

Authors:  Todd E Golde
Journal:  Mol Neurodegener       Date:  2022-03-05       Impact factor: 14.195

6.  Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study.

Authors:  Santiago Bullich; Andre Mueller; Susan De Santi; Norman Koglin; Stephen Krause; June Kaplow; Michio Kanekiyo; Núria Roé-Vellvé; Audrey Perrotin; Aleksandar Jovalekic; David Scott; Michelle Gee; Andrew Stephens; Michael Irizarry
Journal:  Alzheimers Res Ther       Date:  2022-07-27       Impact factor: 8.823

7.  Evaluation of [18F]-JNJ-64326067-AAA tau PET tracer in humans.

Authors:  Suzanne L Baker; Karine Provost; Wesley Thomas; A J Whitman; Mustafa Janabi; Mark E Schmidt; Maarten Timmers; Hartmuth C Kolb; Gil D Rabinovici; William J Jagust
Journal:  J Cereb Blood Flow Metab       Date:  2021-07-14       Impact factor: 6.960

8.  Discriminatory ability of next-generation tau PET tracers for Alzheimer's disease.

Authors:  Steven Y Yap; Barbara Frias; Melissa C Wren; Michael Schöll; Nick C Fox; Erik Årstad; Tammaryn Lashley; Kerstin Sander
Journal:  Brain       Date:  2021-09-04       Impact factor: 13.501

9.  Hippocampal subfield imaging and fractional anisotropy show parallel changes in Alzheimer's disease tau progression using simultaneous tau-PET/MRI at 3T.

Authors:  Mackenzie L Carlson; Tyler N Toueg; M Mehdi Khalighi; Jessa Castillo; Bin Shen; Emily C Azevedo; Phillip DiGiacomo; Nicole Mouchawar; Gustavo Chau; Greg Zaharchuk; Michelle L James; Elizabeth C Mormino; Michael M Zeineh
Journal:  Alzheimers Dement (Amst)       Date:  2021-07-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.